• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zenas BioPharma Inc.

    4/28/25 7:02:48 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    DEFA14A 1 tm2512976d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    SCHEDULE 14A 

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.     )

     

    Filed by the Registrant x 

    Filed by a Party other than the Registrant ¨ 

    Check the appropriate box: 

    ¨ 

    Preliminary Proxy Statement 

    ¨ 

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

    ¨ 

    Definitive Proxy Statement  

    x 

    Definitive Additional Materials 

    ¨ 

    Soliciting Material under §240.14a-12

     

    Zenas BioPharma, Inc. 

    (Name of Registrant as Specified In Its Charter) 

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply): 

    x 

    No fee required.  

    ¨ 

    Fee paid previously with preliminary materials.  

    ¨ 

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    Your Vote Counts! ZENAS BIOPHARMA, INC. 852 WINTER STREET, SUITE 250 WALTHAM, MA 02451 ZENAS BIOPHARMA, INC. 2025 Annual Meeting Vote by June 9, 2025 11:59 PM ET You invested in ZENAS BIOPHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2025. Vote Virtually at the Meeting* June 10, 2025 8:00 am ET Virtually at: www.virtualshareholdermeeting.com/ZBIO2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V67218-P29262 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V67219-P29262 1. To elect the two Class I director nominees named in the Proxy Statement to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Nominees: 1a. Leon O. Moulder, Jr. For 1b. Hongbo Lu, Ph.D. For 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. For NOTE: To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.

    Get the next $ZBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$27.00Buy
    Citigroup
    More analyst ratings

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

      WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management's presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becomin

      5/29/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., Chief Scientific Officer - - Cash, cash equivalents and investments of $314.2 million as of March 31, 2025, expected to provi

      5/15/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase

      4/17/25 4:20:32 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zenas BioPharma Inc.

      10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:25:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:14:53 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

      SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

      5/12/25 10:20:43 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

      WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

      4/7/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

      –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

      3/17/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      11/12/24 10:40:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      10/21/24 4:18:16 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      9/25/24 6:00:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/19/25 4:01:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/11/25 4:20:30 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Zenas Biopharma with a new price target

      Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

      3/20/25 8:00:59 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Zenas Biopharma with a new price target

      Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

      2/4/25 7:13:29 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

      H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

      12/16/24 6:47:20 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Von Moltke Lisa

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/17/25 4:01:17 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Von Moltke Lisa

      3 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      3/21/25 4:01:08 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care